Current BRAF inhibitors block signaling from monomeric BRAFV600E, but not from oncogenic RAS, which requires RAF dimerization. In this issue of Cancer Cell, Yao and colleagues investigate why current drugs are ineffective against RAF dimers, while Peng and colleagues describe a pan-RAF inhibitor targeting both monomeric and dimeric RAF
Purpose: Targeting RAF for anti-tumor therapy in RAS-mutant tumors holds promise. Herein we describe...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
In BRAF V600E melanoma patients, RAF inhibitor treatment causes a MEK-inhibitor-sensitive, RAF-inhib...
In a recent paper, Poulikakos et al. describe a new and potentially common mechanism whereby melanom...
ERK pathway activation in cells expressing wild-type BRAF is a well-reported, clinically-relevant ad...
SummaryLY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies bo...
Current BRAF inhibitors block signaling from monomeric BRAFV600E, but not from oncogenic RAS, which ...
SummaryERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRA...
Tumors with mutant BRAF are dependent on the RAF/MEK/ERK signaling pathway for their growth1-3. We f...
Three papers in Cell and Nature now report that dimeric RAF is a plastic enzyme: blocking one ATP-bi...
Tumours with mutant BRAF are dependent on the RAF-MEK-ERK signalling pathway for their growth. We fo...
RAF inhibitors have the unique property of transactivating RAS-dependent RAF dimers in most cells bu...
NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use ...
RAF research is booming since the discovery of mutant B-RAF in ∼8% of human cancer. One reason for t...
Summary Activated RAS promotes dimerization of members of the RAF kinase family1-3. ATP-competitive ...
Purpose: Targeting RAF for anti-tumor therapy in RAS-mutant tumors holds promise. Herein we describe...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
In BRAF V600E melanoma patients, RAF inhibitor treatment causes a MEK-inhibitor-sensitive, RAF-inhib...
In a recent paper, Poulikakos et al. describe a new and potentially common mechanism whereby melanom...
ERK pathway activation in cells expressing wild-type BRAF is a well-reported, clinically-relevant ad...
SummaryLY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies bo...
Current BRAF inhibitors block signaling from monomeric BRAFV600E, but not from oncogenic RAS, which ...
SummaryERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRA...
Tumors with mutant BRAF are dependent on the RAF/MEK/ERK signaling pathway for their growth1-3. We f...
Three papers in Cell and Nature now report that dimeric RAF is a plastic enzyme: blocking one ATP-bi...
Tumours with mutant BRAF are dependent on the RAF-MEK-ERK signalling pathway for their growth. We fo...
RAF inhibitors have the unique property of transactivating RAS-dependent RAF dimers in most cells bu...
NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use ...
RAF research is booming since the discovery of mutant B-RAF in ∼8% of human cancer. One reason for t...
Summary Activated RAS promotes dimerization of members of the RAF kinase family1-3. ATP-competitive ...
Purpose: Targeting RAF for anti-tumor therapy in RAS-mutant tumors holds promise. Herein we describe...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
In BRAF V600E melanoma patients, RAF inhibitor treatment causes a MEK-inhibitor-sensitive, RAF-inhib...